OpenAI has expanded its healthcare technology ambitions by integrating advanced AI agents into drug development workflows. New tools are designed to help pharmaceutical companies manage research timelines and clinical trial operations.
The technology assists teams with study monitoring, budget tracking, and scheduling challenges while keeping final decisions under human supervision.
Researchers believe AI-assisted development could eventually reduce delays and improve efficiency throughout the lengthy drug approval process.
About the Author
